The Motley Fool

Mesoblast shares halted as it asks investors to tip in another $75 million

Mesoblast limited (ASX: MSB) shares are locked in a trading halt today with the regenerative medicine business reportedly seeking to raise another $75 million according to news reports in the Australian Financial Review.

Mesoblast has often been touted as the next blockbuster company on the ASX and has seen its shares swing wildly in value depending on sentiment and the state of its balance sheet. 

As at June 30 2019 it had US$50.4 million cash on hand but posted a quarterly cash operating loss of US$19.08 million with just $1.038 million in ‘royalty receipts’ received over the quarter.

So given its cash burn rate we can see why the company needs to raise more capital by the issue of another 37.5 million shares at $2 a share according to the AFR.

Bank debt is not really an option for a business like Mesoblast as no mainstream bankers will lend to a company with its kind of cash-burning track record and few assets to securitise against.

The biotech is making progress in commercialising a number of its regenerative medicine products, but it’s been slow going.

For example if we wind the clock back 6 years to the quarter ending June 30 2013 it posted an operating cash loss of A$13.5 million on no sales.

In fairness it’s now starting to bring in decent royalty revenues on sales milestones via partnerships with big pharma. For example over the past 12 months it has earned around US$30.7 million in ‘milestone receipts’.

However, the capital raising story is now so familiar that the heavily dilution means dreams of a sky high share price are all but gone. 

After the latest capital raising it will have over 500 million shares on issue to mean it already has a big market cap around $1.1 billion.

Therefore today’s investors have great expectations in buying a $1 billion biotech business that is still burning through huge amounts of shareholder capital on a regular basis. 

Other speculative healthcare businesses to watch include Avita Medical Ltd (ASX: AVH), Paradigm Biopharmaceuticals Ltd (ASX: PAR) and Opthea Limited (ASX: OPT).

NEW! Top 3 Dividend Bets for 2019

With interest rates likely to stay at rock bottom for months (or YEARS) to come, income-minded investors have nowhere to turn... except dividend shares. That’s why The Motley Fool’s top analysts have just prepared a brand-new report, laying out their top 3 dividend bets for 2019.

Hint: These are 3 shares you’ve probably never come across before.

They’re not the banks. Not Woolies or Wesfarmers or any of the “usual suspects.”

We think these 3 shares offer solid growth prospects over the next 12 months. Each of these three companies boasts fully franked yields and could be a great fit for your diversified portfolio. You’ll discover all three names and codes in "The Motley Fool’s Top 3 Dividend Shares for 2019."

Even better, your copy is free when you click the link below. Fair warning: This report is brand new and may not be available forever. Click the link below to be among the first investors to get access to this timely, important new research!

The names of these top 3 dividend bets are all included. But you will have to hurry. Depending on demand – and how quickly the share prices of these companies move – we may be forced to remove this report.

Click here to claim your free copy right now!

Motley Fool contributor Tom Richardson has no position in any of the stocks mentioned.

You can find Tom on Twitter @tommyr345

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

FREE REPORT: Five Cheap and Good Stocks to Buy now…

Our Motley Fool experts have FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.7% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.